Analysts Viewpoint
Novo Nordisk ADR (NVO) receives a Buy rating from Goldman
While this happened, Goldman initiated its Novo Nordisk ADR [NVO] rating to a Buy in a research note published on
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.